Company intelligence / Profile preview

VistaPath

Cambridge, Massachusetts, United States

Ownership: Private
Employees: ~13
Development stage: Other

Overview

VistaPath provides a commercial AI‑driven digital grossing solution (Sentinel) that automates inspection, inking, measurement, documentation, and tracking of tissue specimens in anatomic pathology labs to improve speed, accuracy, and consistency; it is a workflow and diagnostic-support platform rather than a therapeutic or diagnostic test in clinical trials.[1][2][3][6]

Industry: Digital Health Medical Devices

Partnerships

Gestalt Diagnostics (integration of Sentinel with AIRE AI requisition engine to accelerate pathology digitization)[3]PathAI (collaboration to clinically validate VistaPath Sentinel automated tissue grossing platform)[5]PathGroup (partnership to deploy AI‑powered grossing to improve precision and efficiency in labs)[6]

Beyond the preview

Go deeper on VistaPath.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VistaPath.

Explore the full profile